Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ELVN Enliven Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ELVN
Price (delayed)
$19.65
Market cap
$964.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$862.51M
Highlights
The company's quick ratio has surged by 62% YoY and by 5% QoQ
The company's net income fell by 19% YoY and by 7% QoQ
ELVN's equity is down by 9% YoY and by 7% QoQ
Key stats
What are the main financial stats of ELVN
Market
Valuations
Earnings
Shares outstanding
49.07M
Market cap
$964.21M
Enterprise value
$862.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$110.26M
Net income
-$94.83M
EBIT
-$94.6M
EBITDA
-$93.96M
Free cash flow
-$74M
Per share
Balance sheet
Liquidity
EPS
-$1.92
EPS diluted
-$1.92
Free cash flow per share
-$1.48
Book value per share
$5.88
Revenue per share
$0
TBVPS
$6.05
Total assets
$302.57M
Total liabilities
$14.27M
Debt
$0
Equity
$288.3M
Working capital
$280.35M
Debt to equity
0
Current ratio
21.06
Quick ratio
20.72
Net debt/EBITDA
1.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.1%
Return on equity
-31.8%
Return on invested capital
-49.3%
Return on capital employed
-32.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELVN stock price
How has the Enliven Therapeutics stock price performed over time
Intraday
-2.04%
1 week
-7.14%
1 month
10.58%
1 year
-13.44%
YTD
-12.67%
QTD
-2.04%
Financial performance
How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$110.26M
Net income
-$94.83M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 19% YoY and by 7% QoQ
Enliven Therapeutics's operating income has decreased by 18% YoY and by 5% QoQ
Price vs fundamentals
How does ELVN's price correlate with its fundamentals
Growth
What is Enliven Therapeutics's growth rate over time
Valuation
What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
3.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ELVN's P/B is 39% above its 5-year quarterly average of 2.4 but 10% below its last 4 quarters average of 3.7
ELVN's equity is down by 9% YoY and by 7% QoQ
Efficiency
How efficient is Enliven Therapeutics business performance
Enliven Therapeutics's ROA has decreased by 11% YoY and by 10% from the previous quarter
The return on equity has declined by 10% year-on-year and by 9% since the previous quarter
ELVN's return on invested capital is down by 4% since the previous quarter
Dividends
What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELVN.
Financial health
How did Enliven Therapeutics financials performed over time
The company's quick ratio has surged by 62% YoY and by 5% QoQ
The current ratio has soared by 56% YoY and by 5% from the previous quarter
The debt is 100% less than the equity
ELVN's equity is down by 9% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.